Raymond Dingledine Selected Research

Isoflurophate (DFP)

1/2021	Comparison of neuropathology in rats following status epilepticus induced by diisopropylfluorophosphate and soman.
1/2020	Urethane attenuates early neuropathology of diisopropylfluorophosphate-induced status epilepticus in rats.
1/2020	A rat model of organophosphate-induced status epilepticus and the beneficial effects of EP2 receptor inhibition.
1/2017	Ethylatropine Bromide as a Peripherally Restricted Muscarinic Antagonist.
11/2016	Inhibition of the prostaglandin E2 receptor EP2 prevents status epilepticus-induced deficits in the novel object recognition task in rats.
6/2015	Inhibition of the prostaglandin EP2 receptor is neuroprotective and accelerates functional recovery in a rat model of organophosphorus induced status epilepticus.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Raymond Dingledine Research Topics

Disease

21	Status Epilepticus (Complex Partial Status Epilepticus) 02/2022 - 07/2003
20	Seizures (Absence Seizure) 01/2022 - 06/2002
13	Epilepsy (Aura) 01/2019 - 06/2002
9	Neuroinflammatory Diseases 02/2022 - 08/2012
9	Inflammation (Inflammations) 01/2021 - 10/2007
7	Encephalitis (Encephalitis, Rasmussen) 01/2021 - 02/2013
6	Gliosis 02/2022 - 06/2015
3	Alzheimer Disease (Alzheimer's Disease) 11/2021 - 05/2015
3	Anti-N-Methyl-D-Aspartate Receptor Encephalitis 01/2021 - 01/2019
3	Weight Loss (Weight Reduction) 03/2018 - 02/2013
2	Infections 01/2015 - 10/2007
2	Neurodegenerative Diseases (Neurodegenerative Disease) 01/2014 - 10/2007
2	Temporal Lobe Epilepsy 08/2012 - 07/2003
2	Parkinson Disease (Parkinson's Disease) 06/2010 - 02/2005
2	Neoplasms (Cancer) 07/2008 - 10/2007
1	Cognitive Dysfunction 01/2021
1	Poisoning 01/2021
1	Dyskinesias (Dyskinesia) 01/2021
1	Memory Disorders (Memory Loss) 01/2019
1	Nervous System Diseases (Neurological Disorders) 01/2019
1	Cardiotoxicity 01/2019
1	Autoimmune Diseases of the Nervous System 01/2019
1	Partial Epilepsies (Epilepsy, Partial) 01/2018
1	Coronavirus Infections 07/2011

Drug/Important Bio-Agent (IBA)

11	Pilocarpine (Ocusert)FDA LinkGeneric 02/2022 - 07/2003
8	Dinoprostone (PGE2)FDA Link 01/2021 - 02/2012
6	Isoflurophate (DFP)FDA Link 01/2021 - 06/2015
5	ProstaglandinsIBA 11/2021 - 10/2014
5	Anticonvulsants (Antiepileptic Drugs)IBA 01/2015 - 06/2002
4	AntibodiesIBA 01/2021 - 01/2018
4	Messenger RNA (mRNA)IBA 01/2021 - 05/2007
4	TG6-10-1IBA 01/2020 - 02/2013
3	N-Methyl-D-Aspartate Receptors (NMDA Receptors)IBA 01/2021 - 01/2019
3	Cyclooxygenase 2 (Cyclooxygenase-2)IBA 04/2015 - 02/2013
2	OrganophosphatesIBA 01/2022 - 01/2020
2	InterleukinsIBA 01/2021 - 01/2014
2	Immunoglobulin G (IgG)IBA 01/2021 - 01/2019
2	SomanIBA 01/2021 - 11/2016
2	CytokinesIBA 01/2021 - 06/2015
2	Urethane (Ethyl Carbamate)IBA 01/2020 - 03/2018
2	AlbuminsIBA 01/2019 - 01/2018
2	Cyclooxygenase 2 Inhibitors (COX-2 Inhibitors)IBA 01/2019 - 01/2014
2	Transcription Factors (Transcription Factor)IBA 01/2019 - 12/2012
2	BenzodiazepinesIBA 03/2018 - 01/2015
2	Kainic Acid (Kainate)IBA 01/2017 - 10/2014
2	Pharmaceutical PreparationsIBA 01/2017 - 01/2015
2	RNA (Ribonucleic Acid)IBA 01/2017 - 06/2010
2	Cholinergic Agents (Cholinergics)IBA 01/2017 - 06/2015
1	Cholinesterases (Cholinesterase)IBA 01/2022
1	G-Protein-Coupled Receptors (Receptors, G Protein Coupled)IBA 01/2021
1	Interleukin-1 (Interleukin 1)IBA 01/2021
1	Interleukin 1 Receptor Antagonist Protein (Anakinra)FDA Link 01/2021
1	LigandsIBA 01/2021
1	Monoclonal AntibodiesIBA 01/2021
1	Nerve AgentsIBA 01/2021
1	N-Methylaspartate (NMDA)IBA 01/2021
1	CC ChemokinesIBA 01/2021
1	Interleukin-1 Receptors (Interleukin 1 Receptor)IBA 01/2021
1	fluorophosphate (sodium monofluorophosphate)FDA Link 01/2020
1	Enhancer of Zeste Homolog 2 ProteinIBA 01/2019
1	Peptides (Polypeptides)IBA 01/2019
1	AutoantibodiesIBA 01/2019
1	LipoxinsIBA 01/2019
1	Amyloid (Amyloid Fibrils)IBA 01/2019
1	Prostaglandin D2IBA 01/2019
1	Immunoglobulins (Immunoglobulin)IBA 01/2019
1	LeukotrienesIBA 01/2019
1	EndocannabinoidsIBA 01/2019
1	Diazepam (Valium)FDA LinkGeneric 03/2018
1	Biomarkers (Surrogate Marker)IBA 01/2018
1	HMGB1 Protein (HMG1)IBA 01/2018
1	Isoflurane FDA LinkGeneric 01/2018
1	Losartan (Cozaar)FDA LinkGeneric 01/2018
1	Adenosine (Adenocard)FDA LinkGeneric 01/2018
1	Ammonium CompoundsIBA 01/2017
1	Carbachol (Carbastat)FDA Link 01/2017
1	CalciumIBA 01/2017
1	BromidesIBA 01/2017
1	Atropine FDA LinkGeneric 01/2017
1	Organophosphorus CompoundsIBA 06/2015
1	Proteins (Proteins, Gene)FDA Link 05/2015
1	Advanced Glycation End ProductsIBA 05/2015
1	FructoseIBA 05/2015
1	Kainic Acid Receptors (Kainate Receptor)IBA 10/2014
1	Protein Kinase CIBA 10/2014
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2014
1	ChemokinesIBA 01/2014
1	EnzymesIBA 01/2014
1	Prostaglandin Receptors (Prostaglandin Receptor)IBA 02/2013
1	RE1-silencing transcription factorIBA 12/2012
1	ElementsIBA 12/2012
1	ChromatinIBA 12/2012
1	Prostaglandins EIBA 02/2012
1	Eukaryotic Initiation Factor-4F (EIF4F)IBA 07/2011

Therapy/Procedure

8	Therapeutics 01/2021 - 06/2002
2	Lasers (Laser) 01/2017 - 02/2005
1	Electrodes (Electrode) 01/2021
1	Intraventricular Infusions 01/2019
1	Topical Administration 01/2018
1	Intraperitoneal Injections 11/2016